Work with thought leaders and academic experts in Pharmacology
Companies can greatly benefit from working with experts in the field of Pharmacology. These researchers possess in-depth knowledge of drug interactions, mechanisms of action, and therapeutic applications. By collaborating with them, companies can enhance their research and development efforts, gain insights into new drug targets, optimize drug formulations, and improve clinical trial design. Pharmacology experts can also provide valuable guidance in regulatory affairs, ensuring compliance with safety and efficacy standards. Additionally, their expertise can help companies identify potential drug-drug interactions and adverse effects, leading to safer and more effective medications. Overall, partnering with Pharmacology thought leaders can accelerate innovation, improve product quality, and drive business growth.
Researchers on NotedSource with backgrounds in Pharmacology include Aimee Eggler, Gwendolyn Thomas, Ph.D., CSCS, USAW-L1, Denver Ncube, Ph.D., Regan Hamel, Elvira Forte, Susan Song, MD/PhD, Dushani L. Palliyaguru, Ph.D., Dr. Everson A Nunes, Ph.D., Dr. David Siderovski, Ph.D., Lindsay Webb, PhD, and Katie Barr.
Aimee Eggler
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Expertise
Other Research Expertise (18)
About
Most Relevant Publications (1+)
25 total publications
Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators
Frontiers in Pharmacology / Jun 07, 2021
Repash, E. M., Pensabene, K. M., Palenchar, P. M., & Eggler, A. L. (2021). Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.686201
See Full Profile
Gwendolyn Thomas, Ph.D., CSCS, USAW-L1
Resistance Exercise Physiologist/Performance Enhancement/Optimizing RE Prescription
Most Relevant Research Expertise
Other Research Expertise (30)
About
Most Relevant Publications (1+)
51 total publications
Effect of resistance exercise on muscle steroid receptor protein content in strength-trained men and women
Steroids / Nov 01, 2009
Vingren, J. L., Kraemer, W. J., Hatfield, D. L., Volek, J. S., Ratamess, N. A., Anderson, J. M., Häkkinen, K., Ahtiainen, J., Fragala, M. S., & Thomas, G. A. (2009). Effect of resistance exercise on muscle steroid receptor protein content in strength-trained men and women. Steroids, 74(13–14), 1033–1039. https://doi.org/10.1016/j.steroids.2009.08.002
See Full Profile
Denver Ncube, Ph.D.
Computational biologist/bioinformatician with a passion for extracting meaningful insight from complex biological data.
Most Relevant Research Expertise
Other Research Expertise (4)
About
Most Relevant Publications (1+)
6 total publications
Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats
Journal of Toxicology / Jan 01, 2017
Khoza, S., Moyo, I., & Ncube, D. (2017). Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats. Journal of Toxicology, 2017, 1–9. https://doi.org/10.1155/2017/6746989
See Full Profile
Regan Hamel
Senior bioinformatics scientist, specializing in single cell omics in the context of cellular reprogramming and neuroinflammation
Most Relevant Research Expertise
Other Research Expertise (12)
About
Most Relevant Publications (1+)
12 total publications
Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice
Molecular Therapy / Dec 01, 2020
Braga, A., Bandiera, S., Verheyen, J., Hamel, R., Rutigliani, C., Edenhofer, F., Smith, J. A., & Pluchino, S. (2020). Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice. Molecular Therapy, 28(12), 2677–2690. https://doi.org/10.1016/j.ymthe.2020.08.001
See Full Profile
Elvira Forte
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Other Research Expertise (26)
About
Most Relevant Publications (1+)
63 total publications
New Perspectives to Repair a Broken Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry / Apr 01, 2009
Gaetani, R., Barile, L., Forte, E., Chimenti, I., Ionta, V., Di Consiglio, A., Miraldi, F., Frati, G., Messina, E., & Giacomello, A. (2009). New Perspectives to Repair a Broken Heart. Cardiovascular & Hematological Agents in Medicinal Chemistry, 7(2), 91–107. https://doi.org/10.2174/187152509787847128
See Full Profile
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Other Research Expertise (39)
About
Most Relevant Publications (2+)
97 total publications
Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats
Canadian Journal of Physiology and Pharmacology / Oct 01, 2014
dos Santos, C., Ferreira, F. B. D., Gonçalves-Neto, L. M., Taboga, S. R., Boschero, A. C., & Rafacho, A. (2014). Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats. Canadian Journal of Physiology and Pharmacology, 92(10), 867–878. https://doi.org/10.1139/cjpp-2014-0259
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets / Mar 30, 2017
Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345
See Full Profile
Dr. David Siderovski, Ph.D.
Professor of Computational Pharmacology; Chair of HSC SBS Dept. of Pharmacology & Neuroscience
Most Relevant Research Expertise
Other Research Expertise (25)
About
Most Relevant Publications (7+)
94 total publications
G-protein signaling: back to the future
Cellular and Molecular Life Sciences / Mar 01, 2005
McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P., & Willard, F. S. (2005). G-protein signaling: back to the future. Cellular and Molecular Life Sciences, 62(5), 551–577. https://doi.org/10.1007/s00018-004-4462-3
Regulators of G-Protein signalling as new central nervous system drug targets
Nature Reviews Drug Discovery / Mar 01, 2002
Neubig, R. R., & Siderovski, D. P. (2002). Regulators of G-Protein signalling as new central nervous system drug targets. Nature Reviews Drug Discovery, 1(3), 187–197. https://doi.org/10.1038/nrd747
Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets
Pharmacological Reviews / Jul 07, 2011
Kimple, A. J., Bosch, D. E., Giguère, P. M., & Siderovski, D. P. (2011). Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets. Pharmacological Reviews, 63(3), 728–749. https://doi.org/10.1124/pr.110.003038
Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights
Molecular Pharmacology / Apr 12, 2007
Johnston, C. A., & Siderovski, D. P. (2007). Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights. Molecular Pharmacology, 72(2), 219–230. https://doi.org/10.1124/mol.107.034348
Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique
Neuropsychopharmacology / Jan 11, 2006
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Bell, C., Nos, L., Fried, P., Pearce, D. A., Singh, S., Siderovski, D. P., Willard, F. S., & Fukuda, M. (2006). Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique. Neuropsychopharmacology, 31(9), 1888–1899. https://doi.org/10.1038/sj.npp.1301002
Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors
Molecular Pharmacology / Mar 22, 2006
Hains, M. D., Wing, M. R., Maddileti, S., Siderovski, D. P., & Harden, T. K. (2006). Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors. Molecular Pharmacology, 69(6), 2068–2075. https://doi.org/10.1124/mol.105.017921
Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells
Journal of Pharmacology and Experimental Therapeutics / Oct 25, 2013
Holden, N. S., George, T., Rider, C. F., Chandrasekhar, A., Shah, S., Kaur, M., Johnson, M., Siderovski, D. P., Leigh, R., Giembycz, M. A., & Newton, R. (2013). Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 348(1), 12–24. https://doi.org/10.1124/jpet.113.204586
See Full Profile
Lindsay Webb, PhD
Immunologist and cancer biologist passionate about driving innovative research to improve patient health
Most Relevant Research Expertise
Other Research Expertise (6)
About
Most Relevant Publications (3+)
11 total publications
203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Ding, J., Webb, L., Patterson, T., Fleury, M., Zieba, A., Horton, H., Hofmeister, R., Gutierrez, D., & Tighe, R. (2021). 203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A214–A214. https://doi.org/10.1136/jitc-2021-sitc2021.203
173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Fleury, M., McCarthy, D., Horton, H., Anderson, C., Watt, A., Zieba, A., Webb, L., Ding, J., Tighe, R., Hofmeister, R., & Gutierrez, D. (2021). 173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A185–A185. https://doi.org/10.1136/jitc-2021-sitc2021.173
757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Xu, C., Rabinovich, B., Deshpande, A., Zhou, X., Pipp, F. C., Schweickhardt, R., Webb, L., Yalavarthi, S., Bourin, C., Ghatak, P., Safi, B., Wollerton, F., Brewis, N., Munoz-Olaya, J., Belousova, N., Alimzhanov, M., Hubensack, M., Halle, J.-P., Blaukat, A., & Moisan, J. (2021). 757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A792–A792. https://doi.org/10.1136/jitc-2021-sitc2021.757
See Full Profile
Katie Barr
Bioinformatician and developer with strong academic and commercial experience
Most Relevant Research Expertise
Other Research Expertise (11)
About
Most Relevant Publications (1+)
9 total publications
Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model
Advanced Therapeutics / Oct 09, 2020
de Lázaro, I., Sharp, P., Gurcan, C., Ceylan, A., Stylianou, M., Kisby, T., Chen, Y., Vranic, S., Barr, K., Taheri, H., Ozen, A., Bussy, C., Yilmazer, A., & Kostarelos, K. (2020). Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model. Advanced Therapeutics, 4(1). Portico. https://doi.org/10.1002/adtp.202000109
See Full Profile
Example Pharmacology projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Pharmacology?
Optimizing Drug Formulations
A pharmaceutical company can collaborate with a Pharmacology expert to optimize the formulation of a drug, ensuring its stability, bioavailability, and therapeutic efficacy. The researcher can provide insights into the physicochemical properties of the drug, recommend suitable excipients, and suggest formulation strategies to enhance drug delivery and absorption.
Identifying New Drug Targets
By partnering with a Pharmacology researcher, a biotechnology company can identify novel drug targets for various diseases. The expert can analyze disease mechanisms, molecular pathways, and receptor interactions to identify potential therapeutic targets. This collaboration can lead to the development of innovative drugs with improved efficacy and specificity.
Improving Clinical Trial Design
A contract research organization (CRO) can collaborate with a Pharmacology expert to improve the design of clinical trials. The researcher can provide insights into appropriate dosing regimens, patient selection criteria, and outcome measures. This collaboration can enhance the efficiency and reliability of clinical trials, leading to faster drug approvals and reduced development costs.
Assessing Drug Safety and Efficacy
A pharmaceutical company can work with a Pharmacology expert to assess the safety and efficacy of their drugs. The researcher can conduct preclinical studies, evaluate drug-drug interactions, and assess potential adverse effects. This collaboration can help identify and mitigate safety risks, ensuring the development of safe and effective medications.
Navigating Regulatory Affairs
Companies can collaborate with Pharmacology experts to navigate the complex landscape of regulatory affairs. These researchers can provide guidance on regulatory requirements, assist in preparing documentation for regulatory submissions, and ensure compliance with safety and efficacy standards. This collaboration can streamline the regulatory process and expedite the approval of new drugs.